Abstract
Parkinson’s disease (PD) is morphologically characterized by progressive loss of neurons in the substantia nigra pars compacta (SNpc) and other subcortical nuclei associated with intracytoplasmic Lewy bodies and dystrophic (Lewy) neurites mainly in subcortical nuclei and hippocampus und, less frequently in cerebral cortex. SN cell loss is significantly related to striatal dopamine (DA) deficiency as well as to both the duration and clinical severity of disease, The two major clinical subtypes of PD show different morphologic lesion patterns: the akinetic-rigid form has more severe cell loss in the ventrolateral part of SN with negative correlation to DA loss in the posterior putamen, and motor symptoms related to overacitivty of the GABAergic “indirect” motor loop, which causes inhibition of the glutamatergic thalamocortical pathway and reduced cortical activation. The tremor-dominant type shows more severe cell loss in the medial SNpc and retrorubal field A 8, which project to the matrix of the dorsolateral striatum and ventromedial thalamus, thus causing hyperactivity of thalamomotor and cerebellar projections. These and experimental data suggesting different pathophysiological mechanisms for the major clinical subtypes of PD may have important therapeutic implications.
Lewy bodies, the morphologic markers of PD, are composed of hyperphosphorylated neurofilament proteins, lipids, redox-active iron, ubiquitin, and α-synuclein, showing a continuous accumulation in the periphery and of ubiquitin in the central core. α-synuclein, is usually unfolded in α-helical form. By gene mutation, environmental stress or other factors it can be transformed to β-folding which is sensible to self-aggregation in filamentous fibrils and formation of insoluble intracellular inclusions that may lead to functional disturbances and, finally , to death of involved neurons. While experimental and tissue culture studies suggest that apoptosis, a genetically determined form of programmed cell death, represents the most common pathway in neurodegeneration, DNA fragmentation, overexpression of proapoptotic proteins and activated caspase-3, the effector enzyme of the terminal apopoptic cascade, have only extremely rarely been detected in SN of PD brains. This is in accordance with the rapid course of apoptotis and the extremely slow progression of the neurodegenerative process in PD. The biological role of Lewy bodies and other intracellular inclusions, the mechanisms of the intracellular aggregation of insoluble protein deposits, and their implication for cellular dysfunction resulting in neurodegeneration and cell demise are still unresolved. Further elucidation of the basic molecular mechanisms of cytoskeletallesions will provide better insight into the pathogenesis of neurodegeneration in PD and related disorders.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Albin RL (1995) The pathophysiology of chorea, ballism and parkinsonism. ParkinsonismRel Disord 1: 2–133
Anderson JK (2001) Does neuronal loss in Parkinson’s disease involve programmed celldeath? Bio Essays 23: 640–647
Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, Mouatt-Prient A,Ruberg M, Agid Y (1997) Apoptosis and autophagy in nigral neurons of patients withParkinson’s disease. Histol Histopathol 12: 25–31,1997
Anichtchik OV, Rinne JO, Kalimo H, Panula P (2000) An altered histaminergicinnervation of the substantia nigra in Parkinson’s disease. Exp Neurol 163: 20–30
Antonini A, Moeller JR, Nakamura T, Spetsieris P, Dhawan V, Eidelberg D (1998) Themetabolic anatomy of tremor in Parkinson’s disease. Neurology 51: 803–810
Arai Y,Yamazaki M,Mori O,Muramatsu H, Asano G,Katayama Y,(2001) a-synuclein-positive structures in cases with sporadic Alzheimer’s disease: morphology and itsrelationship to tau aggregation. Brain Res 888: 287–296
Rendt T, Holzer M, Fruth R, Bruckner MK, Gartner U (1998) Phosphorylation of tau,Aβ-formation, and apoptosis after in vivo inhibition of PP-1 and PP-2A. NeurobiolAging 19: 3–13
Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T,(1998) Aggregation of a-synuclein in Lewy bodies of sporadic Parkinson’s diseaseand dementia with Lewy bodies. Am J Pathol 152: 879–884
Banati RB, Daniel SE, Path MRC, Blunt SB (1998) Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson’s disease. Mov Disord 13: 221–227
Benarroch EE, Schmeichel AM, Parisi JE (2000) Involvement of the ventrolateral medulla in parkinsonism with autonomic failure. Neurology 54: 963–968
Benisty S, Boissiere F, Faucheux B, Agid Y, Hirsch EC (1998) TRKB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients ¡ª an in situ hybridization study. Neuroscience 86: 813–826
Berger B, Gaspar P, Verney C (1991) Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. Trends Neurosci 14: 21–27
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger P (1973) Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415–455
Bezard E, Brotchie JM, Gross CE (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2: 577–588
Blandini F, Nappi G, Tassorelli C, Martignoni E (2000) Functional changes of the basal ganglia circuitry in Parkinson’s disease. Prog Neurobiol 62: 63–88
Boecker H, Brooks DJ (1998) Functional imaging of tremor. Mov Disord 13: 64–72
Braak H, Braak E (2000) Pathoanatomy of Parkinson’s disease. J Neurol 247 [Suppl 2]: 113–10
Braak H, Rub U, Sandmann-Keil D, Gai WP, de Vos RA, Jansen Steur EN, Arai K, Braak E (2000) Parkinson’s disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system. Acta Neuropathol 99:489–495
Braak E,Sandmann-Keil D,Rub U,Gai WP,de Vos RAI, Jansen Steur ENH,Arai K, Braak H,(2001) a-synuclein immunopositive Parkinson’s disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol 101:195–202
Broe M, Shephard CE, Milward EA, Halliday GM (2001) Relationship between DNA-fragmentation, morphological changes and dementia with Lewy bodies. Acta Neuropathol 101: 616–624
Calingasan NY, Park LC, Calo LL, Trifiletti RR, Gandy SE, Gibson GE (1998) Induction of nitric oxide synthase and microglial responses precede selective cell death induced by chronic impairment of oxidative metabolism. Am J Pathol 153: 599–610
Cassarino DS, Parks JK, Parker WD, Bennett JP (1999) The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta 1453: 49–62
Castellani RJ, Siedlak SL, Perry G, Smith MA (2000) Sequestration of iron by Lewy bodies in Parkinson’s disease. Acta Neuropathol 100:111–114
Choi WS, Yoon SY, Oh TH, Choi EJ, O’Malley KL, Oh YJ (1999) Two distinct mechanisms are involved in 6-hydroxydopamine-and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J Neurosci Res 57: 86–94
Chung KKK, Dawson VL, Dawson TM (2001) The role of the ubiquitan-proteasomal pathway in Parkinson’s disease and other neurodegenerative disorders. TINS 24 [Suppl]: S7–S14
Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, Miller GW, Mufson EJ, Mash DC, Levey AI (1999) Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 409: 38–56
Clarke PGH, Apoptosis versus necrosis (1999) In: Koliatsosue M, Ratan RR (eds) Cell death and disease of the nervous system. Humana Press, Totowa, pp 3–28
Counihan TJ, PenneyJB, Jr (1998) Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson’s diseased brains. J Neurol Neurosurg Psychiatry 65: 164–169
Dale GE, Probst A, Luthert P, Martin J, Anderton BH, Leigh PN (1992) Relationships between Lewy bodies and pale bodies in Parkinson’s disease. Acta Neuropathol 83: 525–529
Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the humanbrain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease.Brain 122: 1437–1448
Davidson WS,Jonas A,Clayton DF,George JM,(1998) Stabilization of a-synucleinsecondary structure upon binding to synthetic membranes. J Biol Chem 273: 9443–9449
De Ceballos ML, Lopez-Lozano JJ (1999) Subgroups of parkinsonian patients differentiated by peptidergic immunostaining of caudate nucleus biopsies. Peptides 20: 249–257
Deuschl G, Wenzelburger R, Loffler K, Raethjen J, Stolze H (2000) Essential tremor andcerebellar dysfunction clinical and kinematic analysis of intention tremor. Brain 123(Pt 8): 1568–1580
Dickson D, Lin W-l, Liu W-K, Yen S-H (1999) Multiple system atrophy: a sporadicsynucleinopathy. Brain Pathol 9: 721–732
Dragunow M, Faull R,Lawlor P,Beilharz EJ,Singleton K,Walker EB,Mee E,(1995)In situ evidence for DNA fragmentation in Huntington’s disease striatum andAlzheimer’s disease temporal lobes. Neuroreport 6: 1053–1057
Duan W, Zhang Z, Gash DM, Mattson MP (1999) Participation of prostate apoptosisresponse-4 in degeneration of dopaminergic neurons in models of Parkinson’sdisease. Ann Neurol 46: 587–597
Duda JE, Lee VMY, Trojanowski JQ (2000) Neuropathology of synuclein aggregates. Newinsights into mechanism of neurodegenerative diseases. J Neurosci Res 61:121–127
Eberling JL, Pivirotto P, Bringas J, Bankiewicz KS (2000) Tremor is associated with PETmeasures of nigrostriatal dopamine function in MPTP-lesioned monkeys. Exp Neurol 165: 342–346
Eve DJ, Nisbet AP, Kingsburg AE, Temlett J, Marsden CD, Foster UJF (1997) Selectiveincrease in somatostatin mRNA expression in human basal ganglia in Parkinson’sdisease. Mol Brain Res 50: 59–70
Farrer M, Gwinn-Hardy K, Hutton M, Hardy J (1999) The genetics of disorders withsynuclein pathology and parkinsonism. Hum Mol Genet 8:1901–1905
Fearnley JM, Lees AJ (1994) Pathology of Parkinson’s disease. In: Calne DB (ed)Neurodegenerative diseases. Saunders, Philadelphia, pp 545–554
Ferrer I, Blanco R, Cutillas B, Ambrosio S (2000) Fas and Fas-L expression in Huntington’s disease and Parkinson’s disease.Neuropathol Appl Neurobiol 26: 424–433
Ferrer I, Blanco R, Marmona M, Puig B, Barrachina M, Gomec C, Ambrosio S, (2001)Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-jun, N-terminal kinase (SAPK/JNK) and p38kinase expression in Parkinson’s disease and dementia with Lewy bodies. J NeuralTransm 108: 1383–1396
Forno LS (1996) Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 55:259–272
Gai WP, Yuan HX, Li XQ, Power JT, Blumbergs PC, Jensen PH (2000) In situ and invitro study of colocalization and segregation of a-synuclein, ubiquitin, and lipids inLewy bodies. Exp Neurol 166: 324–333
Galvin JF, Lee VMY, Schmidt L, Tu P-H, Iwatsubo T, Trojanowski JQ, (1999)Pathobiology of the Lewy body. Adv Neurol 80: 313–324
Galvin JE, Lee VM,Trojanowski JQ,(2001) Synucleinopathies: clinical and pathologicalimplications. Arch Neurol 58:186–190
Elb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. ArchNeurol 56: 33–39
Gerfen C (1992) The neostriatal mosaic: multiple levels of compartmental organization.Trends Neurosci 15:133–139
Gleckman AM, Jiang Z, Liu Y, Smith TW (1999) DNA fragmentation in neuronsand glial cells indicates cellular injury but not apoptosis in Pick’s disease. ActaNeuropathol 98: 55–61
Goldberg MS, Lansbury FT (2000) Is there a cause-and-effect relationship between a-synuclein fibrillation and Parkinson’s disease? Nat Cell Biol 2: E115–E119
Gomez-Tortosa E, Newell K,Irizarry MC,Sanders JL,Hyman BT,(2000) alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological stagingand comparison with ubiquitin immunostaining. Acta Neuropathol 99: 352–357
Graeber MB, Grasbon-Frodl E, Abell-Aleff P, et al (1999) Nigral neurons are likely to dieof a mechanism other than classical apoptosis in Parkinson’s disease. ParkinsonismRel Disord 5: 187–192
Graham JM, Sagar HJ (1999) A data-driven approach to the study of heterogeneitiy inidiopathic Parkinson’s disease: identification of three distinct subgroups. Mov Disord 14: 10–20
Groenewegen HJ (1997) Cortical-subcortical relationships and the limbic forebrain. In:Timble MR, Cummings JL (eds) Contemporary behavioral neurology. Butterworth-Heinemann, Boston, pp 29–48
Guttman M, Burkholder J, Kish SJ, Hussey D, Wilson A, DaSilva J, Houle S, (1997)[HC]RTI-32 PET studies of the dopamine transporter in early dopa-naiveParkinson’s disease: implications for the symptomatic threshold. Neurology 48:1578–1583
Halliday GM, McRitchie DA, Cartwright HR, Pamphlett HS, Hely MA, Morris JGL,(1996) Midbrain neuropathology in idiopathic Parkinson’s disease and diffuse Lewybody disease. J Clin Neurosci 3: 52–60
Hardman CD, Halliday GM (1999a) The external globus pallidus in patients withParkinson’s disease and progressive upranuclear palsy. Mov Disord 14: 626–633
Hardman CD, Halliday GM (1999b) The internal globus pallidus is affected in progressive supranuclear palsy and Parkinson’s isease. Exp Neurol 158:135–142
Hardman CD, Halliday GM, McRitchie DA, Morris JGL (1997) The subthalamic nucleusin Parkinson’s disease and progressive supranuclear palsy. J Neuropathol Exp Neurol 56: 132–142
Hartmann A, Hirsch EC (2001) Parkinson’s disease: the apoptosis hypothesis revisited.Adv Neurol 86:143–153
Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A,Turmel H, Srinivasan A, Ruberg M, Evan GI, Agid Y, Hirsch EC (2000) Caspase-3.A vulnerability factor and final effector in apoptotitc death of dopaminergic neuronsin Parkinson’s disease. Proc Natl Acad Sci USA 97: 2875–2880
Hartmann A, Troadec JD, Hunot S, Kikly K, Faucheux BA, Mouatt-Prigent A, Ruberg M, Agid Y, Hirsch EC (2001) Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson’s disease, but pathway inhibition results in neuronal necrosis. J Neurosci 21: 2247–2255
Hartmann A, Mouatt-Prigent A, Faucheux BA, Agid Y, Hirsch EC (2002) FADD: A linkbetween TNF family receptors and caspases in Parkinson’s disease. Neurology 58:308–310
Hashimoto M, Masliah E, (1999) a-synuclein in Lewy body disease and Alzheimer’sDisease. Brain Pathol 9: 707–720
He Y, Lee T, Leong SK, (2000) 6-hydroxydopamine induced apoptosis of dopaminergiccells in the rat substantia nigra. Brain Res 858: 163–166
Henderson JM, Carpenter K, Cartwright H, Halliday GM,(2000) Degeneration of thecentre median-parafascicular complex in Parkinson’s disease. Ann Neurol 47: 345–352
Hirsch EC (2000) Glial cells and Parkinson’s disease. J Neurol 247 [Suppl 2]: 1158–62
Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, Donnan GA,(2000) Reduced BDNF mRNA expression in the Parkinson’s disease substantianigra. Exp Neurol 166: 127–135
Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, Wong J (2000) a-synuclein promotes mitochondrial deficit andoxidative stress. Am J Pathol 157: 401–440
Hughes AJ, Daniel SE, Lees AJ (2001) Improved accuracy of clinical diagnosis of Lewybody Parkinson’s disease. Neurology 57: 1497–1499
Hughes AJ, Daniel SEW, Ben-Shlomo Y, Lees AJ (2002) The accuracy of diagnosis ofparkinsonian syndromes in a specialist movement disorder service. Brain 125: 861–870
Ito H, Kusaka H, Matsumoto S, Imai T (1996) Striatal efferent involvement and itscorrelation to levodopa efficiacy in patients with multiple system atrophy. Neurology47: 1291–1299
Itoh K, Weis S, Mehraein P, Muller-Hocker J (1997) Defects of cytochrome c oxidase in the substansia nigra of Parkinson’s disease: an immunohistohcemical and morpho-metric study. Mov Disord 12: 9–16
Ito K, Morrish PK, Rakshi JS, Uema T, Ashburner J, Bailey DL, Friston KJ, Brooks DJ,(1999) Statistical parametric mapping with 18F-dopa PET shows bilaterally reducedstriatal and nigral dopaminergic function in early Parkinson’s disease. J NeurolNeurosurg Psychiatry 66: 754–758
Jellinger KA (1991) Pathology of Parkinson’s disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 14: 153–197
Jellinger KA (1998) Neuropathology of movement disorders. Neurosurg Clin North Am 9: 237–262
Jellinger KA (1999) Post mortem studies in Parkinson’s disease ¡ª is it possible to detect brain areas for specific symptoms? J Neural Transm [Suppl] 56: 1–29
Jellinger KA (2000) Cell death mechanisms in Parkinson’s disease. J Neural Transm 107:1–29
Jellinger KA (2001a) The pathology of Parkinson’s disease. Adv Neurol 86: 55–72
Jellinger KA (2001b) Cell death mechanisms in neurodegeneration. J Cell Mol Med 5:1–17
Jellinger KA, Stadelmann C (2000) The enigma of cell death in neurodegenerativedisorders. J Neural Transm [Suppl] 60: 365–380
Jenner P (1998) Oxidative mechanisms in nigral cell death in Parkinson’s disease. MovDisord 13: 24–34
Jha N, Jurma OP, Lalli G, Liu Y, Pettus EH, Greenamyre JT, Liu RM,(2000) Gluthathione depletion in PC12 results in selective inhibitationof mitochondrial complex I activity: implications for Parkinson’s disease. J Biol Chem 275: 26096–26101
Kassubek J, Jungling FD, Hellwig B, Spreer J, Lucking CN (2002) Thalamic gray matterchanges in unilateral parkinsonian resting tremor: a voxel-based morphametricanalysis of 3-dimensional magnetic resonance imaging. Neurosci Lett 323: 29–32
Kholodilov NG,Burke RE (1999) Synuclein expression is decreased in ratsubstantia nigra following induction of apoptosis by intrastriatal 6-hydroxydopamine.Neurosci Lett 275: 105–108
Kingsbury AE, Mardsen CD, Foster OJF (1998) DNA fragmentation in human substantia nigra: apoptosis or perimortem effect? Mov Disord 13: 877–884
Kingsbury AE, Marsden CD, Foster OJF (1999) The vulnerability of nigral neurons toParkinson’s disease is unrelated to their intrinsic capacity for dopamine synthesis: anin situ hybridisation study. Mov Disord 14: 206–219
Kingsbury AE, Cooper M, Schapira AH, Foster OJ (2001) Metabolic enzyme expressionin dopaminergic neurons in Parkinson’s disease: an in situ hybridization study. AnnNeurol 50: 142–149
Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in thestriatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinicalimplications. N Engl J Med 318: 876–880
Lach H, Grimes D, Benoit B, Minkiewicz-Janda A (1992) Caudate nucleus pathology inParkinson’s disease. Ultrastructural and biochemical findings in biopsy material. ActaNeuropathol 83: 352–360
Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D (1999) Evidenceof active nerve cell degeneration in the substantia nigra of humans years afterl-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine exposure. Ann Neurol 46: 598–605
Lassman H, Bancher C, Breitschopf H, Wegiel J, Bobinski M, Jellinger K, WisniewskiHM (1995) Cell death in Alzheimer’s disease evaluated by DNA fragmentation insitu. Acta Neuropathol 89: 35–41
Lee MS, Kim YD, Im JH, Rinne JO, Bhatia KP, (1999) 123 I-IPT brain SPECT study in essential tremor and Parkinson’s disease. Neurology 52: 1422–1426
Levin S, Bucci TJ, Cohen SM, Fix AS, Hardisty JF, LeGrand EK, Maronpot RR, Trump BF (1999) The nomenclature of cell death: recommendations of an ad hoc committee of the Society of Toxicologic Pathologists. Toxic Pathol 27: 484–490
Linert W, Jellinger KA (2001) Cell death mechanisms and the role of iron in neurodegeneration. In: Segura-Aguilar J (ed) Mechanisms of degeneration and protection of the dopaminergic system. FP Graham Publishing, Johnson City, pp 22–65
Litvan I, Maclntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, Bartko JJ,Jankovic J, McKee A, Brandel JP, Chaudhuri KR, Lai EC, D’Olhaberriague L,Pearce RK, Agid Y (1998) Accuracy of the clinical diagnoses of Lewy body disease,Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. ArchNeurol 55: 969–978
Ma SY, Rinne JO, Collan Y, Roytta M, Rinne UK (1995) A quantitative morphometricalstudy of the neuron degeneration in the substantia nigra in patients with Parkinson’sdisease. J Neurol Sci 140: 40–45 Ma SY, Roytta M, Rinne JO, Collam Y, Rinne UK (1997) Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson’s diseaseusing disector counts. J Neurol Sci 151: 83–87
Ma SY, Ciliax BJ, Stebbins G, Jaffar S, Joyce JN, Cochran EJ, Kordower JH, Mash DC,Levey AI, Mufson EJ (1999a) Dopamine transporter-immunoreactive neuronsdecrease with age in the human substantia nigra. J Comp Neurol 409: 25–37
Ma SY, Roytta M, Collan Y, Rinne OJ (1999b) Unbiased morphometrical measurementsshow loss of pigmented nigral neurones with ageing. Neuropathol Appl Neurobiol 25:394–399
Majno G, Joris I (1995) Apoptosis, oncosis, and necrosis. An overview of cell death. AmJ Pathol 146: 3–15
Marshall KA, Daniel SE, Cairns N, Jenner P, Halliwell B (1997) Upregulation of the anti-apoptotic protein Bcl-2 may be early event in neurodegeneration: studies on Parkinson’s incidental Lewy body disease. Biochem Biophys Res Commun 240: 84–87
Mattson MP (2000) Apoptosis in neurodegenerative disorders. Nature Rev Mol Cell Biol 2: 120–129
McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113–1124
McNaught K StP, Olanow CW, Halliwell B, Isacson O, Jenner P (2001) Failure of the ubiquitin-proteasome system in arkinson’s disease. Nature Revs 2: 589–594
McNaught KStP, Lee MH, Hyun D-H, Jenner P (2001) Glial cells and abnormal proteinhandling in the pathogenesis of Parkinson’s disease. Adv Neurol 86: 73–82
McRitchie DA, Cartwright HR, Halliday GM (1997) Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson’s disease. Exp Neurol 144: 202–213
Miller GW, Staley JK, Heilman CJ, Perez JT, Mash DC, Rye DB, Levey AI (1997) Immunochemical analysis of dopamine transporter protein in Parkinson’s disease.Ann Neurol 41: 530–539
Miller GW, Erickson JD, Perez JT, Penland SN, Mash DC, Rye DB, Levey AI (1999) Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson’s disease. Exp Neurol 156: 138–148
Mochizuki H, Mori H, Mizuno Y (1997) Apoptosis in neurodegenerative disorders.J Neural Transm [Suppl] 50: 125–140
Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T (1999) Brain-derived growth factor and nerve growth factor concentrations are de creased in the substantia nigra in Parkinson’s disease. Neurosci Lett 270: 45–48
Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T (2000) Caspase activities and tumor necrosis factor receptor Rl (p55) level are elevated in the substantia nigra from Parkinsonian brains. J Neural Transm 107: 335–341
Morrish PK, Sawle GV, Brooks DJ (1996) Regional changes in [18F]dopa metabolism inthe striatum in Parkinson’s disease. Brain 119: 2097–2103
Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ (1998) Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64: 314–319
Morsch R, Simon W, Coleman PD (1999) Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 58: 188–197
Mouatt-Prigent A, Agid Y, Hirsch EC (1994) Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson’s disease? Brain Res 668: 62–70
Mouatt-Prigent A, Karlsson JO, Yelnik J, Agid Y, Hirsch EC (2000) Calpastatin immu-noreactivity in the monkey and human brain of control subjects and patients with Parkinson’s disease. J Comp Neurol 419: 175–192
Mouradian MM (2002) Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 58: 179–185
Munch G, Luth HJ, Wong A, Arendt T, Hirsch E, Ravid R, Riederer P (2000) Crosslinking of a-synuclein by advanced glycation endproducts ¡ª an earlypathophysiological step in Lewy body formation? J Chem Neuroanat 20: 253–257
Nakamura S, Kawamoto Y, Nakano S, Akiguchi I, Kimura J (1998) Cyclin-dependent kinase 5 and mitogen-activated protein kinase in glial cytoplasmic inclusions in multiple system atrophy. J Neuropathol Exp Neurol 57: 690–698
Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA,(1999) Both familial Parkinson’s disease mutations accelerate a-synuclein aggregation. J Biol Chem 273:9843–9846
Neill TH, Brown SA, Rafols JA, Shoulson L (1998) Atrophy of medium spiny type I striatal dendrites in advanced Parkinson’s disease. Brain Res 455: 148–152
Neystat M,Lynch T,Przedborski S,Kholodilov N,Rzhatskaya M,Burke RE,(1999) a-synuclein expression in substantia nigra and cortex in Parkinson’s disease. Mov Disord 14: 417–422
Nicotra A, Parvez SH (2000) Cell death induced by MPTP, a substrate for monoamine oxidase B. Toxicology 153: 157–166
Obeso JA, Guridi J, DeLong M (1997) Surgery for Parkinson’s disease. J NeurolNeurosurg Psychiatry 62: 2–8
Oh JH, Choi WS, Kim JE, See JW, O’Malley KL, Oh YJ (1998) Overexpression of HA-BAX but not Bcl-2 or Bcl-xL attenuates 6-hydroxydopamine induced neuronalapoptosis. Exp Neurol 154:193–198
Olanow CW, Tatton WG (1999) Etiology and pathogenesis of Parkinson’s disease. Ann Rev Neurosci 22:123–144
Orth M, Schapira AHV (2001) Mitochondria and degenerative disorders. Am J MedGenet 106: 27–36
Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Yoshida T, Fukumura T,Masuda K, Kato M (1996) Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson’s disease: correlations with the three main symptoms. J Neurol Sci 136: 169–173
Parain K, Murer MG, Yan Q, Faucheux B, Agid Y, Hirsch E, Raisman-Vozari R (1999) Reduced expression of brain-derived neurotrophic factor protein in Parkinson’s disease substantia nigra. Neuroreport 10: 557–561
Parent A, Parent M, Levesque M (1999) Basal ganglia and Parkinson’s disease: an anatomical perspective. Neurosci News 2:19–26
Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subtypes of Parkinson’s disease. J Neuropathol Exp Neurol 50: 143–155
Perry G, Numomura A, Lucassen PJ, Lassmann H, Smith MA (1998) Apoptosis and
Alzheimer’s disease. Science 282:1265 Probst-Cousin S, Rickert CH, Schmid KW, Gullotta F (1998) Cell mechanisms in multiple
systematrophy. J Neuropathol Exp Neurol 57: 814–821 Reed JC, (2000) Mechanisms of apoptosis. Am J Pathol 157:1415–1430
Reichmann H, Janetzky B (2000) Mitochondrial dysfunction ¡ª a pathogenetic factor inParkinson’s disease. J Neurol 247 [Suppl 2]: 1163–68
Riederer P, Reichmann H, Janetzky B, Sian J, Lesch K-P, Lange KW, Double KL,Nagatsu T, Gerlach M (2001) Neural degeneration in Parkinson’s disease. Adv Neurol 86:125–136
Roth KA, Kuan C-Y, Haydar TF, D’Sa-Eipper C, Shindler KS, Zheng TS, Kuida K, Flavell RA, Rakic P (2000) Epistatic and independent functions of caspase-3 and Bel-XL in developmental programmed cell death. Proc Natl Acad Sci USA 97: 466–471
Saha AR, Ninkina NN, Hanger DP, Anderton BH, Davies AM, Buchman VL (2000) Induction of neuronal death by a-synuclein. Eur J Neurosci 12: 3073–3077
Sakamoto M, Uchihara T, Hayashi M, Nakamura A, Kikuchi E, Mizutani T, Mizusawa H,Hirai S (2002) Heterogeneity of nigral and cortical Lewy bodies differentiated by amplified triple-labeling of alpha-synuclein, ubiquitin and thiazin red. Exp Neurol (inpress)
Saporito MS, Thomas BA,Scott RW,(2000) MPTP activates c-Jun NH2-terminal kinase(JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo.J Neurochem 75:1200–1208
Schapira AHV (2001) Causes of neuronal death in Parkinson’s disease. Adv Neurol 86:155–162
Schwab C, Schulzer M, Steele JC, McGeer PL (1999) On the survival time of a tangled neuron in the hippocampal CA4 region in parkinsonism dementia complex of Guam. Neurobiol Aging 20: 57–63
Sharma N, Hewett J, Ozelius LJ, Ramesh V, McLean PJ, Breakefield XO, Hyman BT (2001) A close association of torsinA and a-synuclein in Lewy bodies: a fluorescence resonance energy transfer study. Am J Pathol 159: 339–344
Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ (2001) Ubiquitination of a new form of a-synucleinby parkin from human brain: implications for Parkinson’s disease. Science 293: 263–269
Silva MT, Schapira AHV (2001) Parkinson’s disease. In: Mattson MP (ed) Pathogenesisof neurodegenerative disorders. Human Press, Totowa, pp 53–79
Smith MA, Raina AK, Nunomura A, Hochman A, Takeda A, Perry G (2000) Apoptosisin Alzheimer disease: fact or fiction. Brain Pathol 10: 797
Stadelmann C, Lassmann H (2000) Detection of apoptosis in tissue sections. Cell Tissue Res 301:19–31
Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M, (1998) a-synuclein in ilamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95: 6469–6473
Stadelmann C, Lassmann H (2000) Detection of apoptosis in tissue sections. Cell Tissue Res 301:19–31
Stadelmann C, Deckwerth TL, Srinivasan A, Bancher C, Briick W, Jellinger K, Lassmann H (1999) Activation of caspase-3 in single apopototic neurons and granules of granulovacuolar degeneration in Alzheimer disease and Down’s syndrome: a role for autophagy as antiapoptotic counterregulatory mechanism? Am J Pathol 155: 1459–1466
Tatton NA (2000) Increased caspase-3 and BAX immunoreactivity accompanying nuclear GAPDH translocation and neuronal apoptosis in Parkinson’s disease. Exp Neurol 166: 29–43
Tatton WG, Olanow CW (1999) Apoptosis in neurodegenerative diseases: the role of mitochondria. Biochem Biophys Acta 1410:195–214
Tompkins MM, Hill WD (1997) Contribution of somal Lewy bodies to neuronal death. Brain Res 775: 24–29
Tompkins MM, Basgall EJ, Zamrini E, Hill WD (1997) Apoptotic-like changes in Lewy body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol 150:119–131
Uhl GR (1998) Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson’s disease. Ann Neurol 43: 555–560
Varastet M, Riche D, Maziere M, Hantraye P (1994) Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons in Parkinson’s disease. Neuroscience 63: 47–56
Vila M, Wu DC, Przedborski S (2001) Engineered modeling and the secrets of Parkinson’s disease. TINS 24 [Suppl]: S49–S55
Wakabayashi K, Hayashi S, Kakita A, Yamada M, Toyoshima Y, Yoshimoto M, Takahashi H (1998) Accumulation of a-synuclein MACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol 96: 445–452
Wakabayashi K, Engelender S, Yoshimoto M, Tsuji S, Ross CA, Takahashi H (2000) Synphilin-1 is present in Lewy bodies in Parkinson’s disease. Ann Neurol 47:521–523
Walker DG, Terai K, Matsuo A, Beach TG, McGeerEG, McGeer PL (1998) Immunohis-tochemical analyses of fibroblast growth factor receptor-1 in the human substantia nigra ¡ª comparison between normal and parkinson’s disease cases. Brain Res 794: 181–187
Wang KKW (2000) Calpain and caspase: can you tell the difference? Trends Neurol Sci 23: 20–26
Wolozin B, Behl C (2000) Mechanisms of neurodegenerative disorders, part I. Protein aggregates. Arch Neurol 57: 793–796
Wiillner U, Kornhuber J, Weller M, Schulz JB, Loschmann PA, Riederer P (1999) Cell death and apoptosis regulating proteins in Parkinson’s disease ¡ª a cautionary note. Acta Neuropathol 97: 408–412
Wyllie AH, Kerr JFR, Currie AR (1980) Cell death: the significance of apoptosis. Int Rev Cytol 68: 251–305
Yuan JY, Yankner BA (2000) Apoptosis in the nervous system. Nature 407: 802–809
Zecca L, Gallorini M, Schunemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, Tampellini D (2001) Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 76:1766–1773
Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG, Montine TJ (1999) Parkinson’s disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154: 1423–1429
Zirh TA, Lenz FA, Reich SG, Dougherty PM (1998) Patterns of bursting occurring in thalamic cells during parkinsonian tremor. Neuroscience 83:107–121
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Wien
About this paper
Cite this paper
Jellinger, K.A. (2002). Recent developments in the pathology of Parkinson’s disease. In: Jellinger, K.A., Schmidt, R., Windisch, M. (eds) Ageing and Dementia Current and Future Concepts. Journal of Neural Transmission. Supplementa, vol 62. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6139-5_33
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6139-5_33
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83796-2
Online ISBN: 978-3-7091-6139-5
eBook Packages: Springer Book Archive